BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

761 related articles for article (PubMed ID: 34638609)

  • 1. Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy.
    Yan L; Tan Y; Chen G; Fan J; Zhang J
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
    Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
    Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunometabolism: A new target for improving cancer immunotherapy.
    Guo C; Chen S; Liu W; Ma Y; Li J; Fisher PB; Fang X; Wang XY
    Adv Cancer Res; 2019; 143():195-253. PubMed ID: 31202359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reprogramming Tumor Blood Vessels for Enhancing Immunotherapy.
    Schmittnaegel M; De Palma M
    Trends Cancer; 2017 Dec; 3(12):809-812. PubMed ID: 29198436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies.
    Dong Y; Wan Z; Gao X; Yang G; Liu L
    Front Immunol; 2021; 12():609762. PubMed ID: 33968014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking inflammation to improve immunotherapy of advanced cancer.
    Macciò A; Madeddu C
    Immunology; 2020 Apr; 159(4):357-364. PubMed ID: 31821533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD147‑mediated reprogrammed glycolytic metabolism potentially induces immune escape in the tumor microenvironment (Review).
    Li X; Xu W
    Oncol Rep; 2019 May; 41(5):2945-2956. PubMed ID: 30864716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
    Bahrambeigi S; Shafiei-Irannejad V
    Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy.
    Kishton RJ; Sukumar M; Restifo NP
    Cell Metab; 2017 Jul; 26(1):94-109. PubMed ID: 28683298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting PPAR ligands as possible approaches for metabolic reprogramming of T cells in cancer immunotherapy.
    Bahrambeigi S; Molaparast M; Sohrabi F; Seifi L; Faraji A; Fani S; Shafiei-Irannejad V
    Immunol Lett; 2020 Apr; 220():32-37. PubMed ID: 31982460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy.
    Lian X; Yang K; Li R; Li M; Zuo J; Zheng B; Wang W; Wang P; Zhou S
    Mol Cancer; 2022 Jan; 21(1):27. PubMed ID: 35062950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell Fate Reprogramming in the Era of Cancer Immunotherapy.
    Zimmermannova O; Caiado I; Ferreira AG; Pereira CF
    Front Immunol; 2021; 12():714822. PubMed ID: 34367185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysfunctional T cell metabolism in the tumor microenvironment.
    Beckermann KE; Dudzinski SO; Rathmell JC
    Cytokine Growth Factor Rev; 2017 Jun; 35():7-14. PubMed ID: 28456467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression.
    Yang E; Wang X; Gong Z; Yu M; Wu H; Zhang D
    Signal Transduct Target Ther; 2020 Oct; 5(1):242. PubMed ID: 33077737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic checkpoints and novel approaches for immunotherapy against cancer.
    Li Y; Tang J; Jiang J; Chen Z
    Int J Cancer; 2022 Jan; 150(2):195-207. PubMed ID: 34460110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating T cell metabolism in cancer immunotherapy.
    Dugnani E; Pasquale V; Bordignon C; Canu A; Piemonti L; Monti P
    Cancer Lett; 2017 Dec; 411():12-18. PubMed ID: 28974448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
    Clappaert EJ; Murgaski A; Van Damme H; Kiss M; Laoui D
    Front Immunol; 2018; 9():2250. PubMed ID: 30349530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCL21 Programs Immune Activity in Tumor Microenvironment.
    Sharma S; Kadam P; Dubinett S
    Adv Exp Med Biol; 2020; 1231():67-78. PubMed ID: 32060847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of Immune Cell Functions by Metabolic Reprogramming.
    Kim J
    J Immunol Res; 2018; 2018():8605471. PubMed ID: 29651445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
    Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
    Front Immunol; 2018; 9():1288. PubMed ID: 29915603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.